Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

Actualizado

03/06/2021 - 12:00

Reviewed

Jun. 03, 2021

Appendix B: Drug Characteristics Tables

Characteristics of the gp120 Attachment Inhibitor

Appendix B, Table 10. Characteristics of the gp120 Attachment Inhibitor
Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendations	Serum Half-Life	Elimination/ Metabolic Pathway	Adverse Events
Fostemsavir (FTR) Rukobia	600-mg extended-release tablets	FTR 600 mg PO twice daily	11 hours	Hydrolysis (esterases), CYP3A4	Nausea QTc prolongation was seen at 4 times the recommended dose. Use with caution in patients with preexisting heart disease, QTc prolongation, or concomitant use of medications that may prolong QTc interval. Transaminase elevation; transient bilirubin elevation Sleep disturbance, dizzines
Key: CYP = cytochrome P; FTR = fostemsavir; PO = orally; QTc = corrected QT interval

Appendix B: Drug Characteristics Tables

Characteristics of the gp120 Attachment Inhibitor

Appendix B, Table 10. Characteristics of the gp120 Attachment Inhibitor
Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendations	Serum Half-Life	Elimination/ Metabolic Pathway	Adverse Events
Fostemsavir (FTR) Rukobia	600-mg extended-release tablets	FTR 600 mg PO twice daily	11 hours	Hydrolysis (esterases), CYP3A4	Nausea QTc prolongation was seen at 4 times the recommended dose. Use with caution in patients with preexisting heart disease, QTc prolongation, or concomitant use of medications that may prolong QTc interval. Transaminase elevation; transient bilirubin elevation Sleep disturbance, dizzines
Key: CYP = cytochrome P; FTR = fostemsavir; PO = orally; QTc = corrected QT interval

Download Guidelines

Section OnlyPDF (169.95 KB)
Full GuidelinePDF (5.07 MB)
Recommendations OnlyPDF (229.24 KB)
Tables OnlyPDF (939.48 KB)